Child Growth According to Maternal and Child HIV Status in Zimbabwe

Adetayo O Omoni, Robert Ntozini, Ceri Evans, Andrew J Prendergast, Lawrence H Moulton, Parul S Christian, Jean H Humphrey, Adetayo O Omoni, Robert Ntozini, Ceri Evans, Andrew J Prendergast, Lawrence H Moulton, Parul S Christian, Jean H Humphrey

Abstract

Background: Growth failure is common among HIV-infected infants, but there are limited data on the effects of HIV exposure or timing of HIV acquisition on growth.

Methods: Fourteen thousand one hundred ten infants were enrolled in the Zimbabwe Vitamin A for Mothers and Babies trial in Zimbabwe before the availability of antiretroviral therapy or co-trimoxazole. Anthropometric measurements were taken from birth through 12-24 months of age. Growth outcomes were compared between 5 groups of children: HIV-infected in utero (IU), intrapartum (IP) or postnatally (PN); HIV-exposed uninfected (HEU); and HIV unexposed.

Results: Growth failure was common across all groups of children. Compared with HIV-unexposed children, IU-, IP- and PN-infected children had significantly lower length-for-age and weight-for-length Z scores throughout the first 2 years of life. At 12 months, odds ratios for stunting were higher in IU [6.25, 95% confidence interval (CI): 4.20-9.31] and IP infants (4.76, 95% CI: 3.58-6.33) than in PN infants (1.70, 95% CI: 1.16-2.47). Compared with HIV-unexposed infants, HEU infants at 12 months had odds ratios for stunting of 1.23 (95% CI: 1.08-1.39) and wasting of 1.56 (95% CI: 1.22-2.00).

Conclusions: HIV-infected infants had very high rates of growth failure during the first 2 years of life, particularly if IU or IP infected, highlighting the importance of early infant diagnosis and antiretroviral therapy. HEU infants had poorer growth than HIV-unexposed infants in the first 12 months of life.

Figures

FIGURE 1.
FIGURE 1.
Mean length-for-age (A) and weight-for-length (B) Z scores from birth to 24 months according to child HIV status and timing of infection. A: N for IU at baseline, 6 weeks, 6, 12, 18 and 24 months is 380, 264, 142, 103, 52 and 34, respectively. N for IP at 6 weeks, 6, 12, 18 and 24 months is 502, 284, 200, 102 and 57, respectively. N for PN at 6, 12, 18 and 24 months is 77, 138, 97 and 80, respectively. N for HEU at baseline, 6 weeks, 6, 12, 18 and 24 months is 3993, 2365, 2181, 1916, 1007 and 714, respectively. N for unexposed at baseline, 6 weeks, 6, 12, 18 and 24 months is 9053, 6233, 6439, 6212, 1733 and 1220, respectively. B: N for IU at baseline, 6 weeks, 6, 12, 18 and 24 months is 342, 262, 142, 103, 52 and 34, respectively. N for IP at 6 weeks, 6, 12, 18 and 24 months is 449, 498, 282, 199, 102 and 56, respectively. N for PN at 6, 12, 18 and 24 months is 77, 138, 96 and 79, respectively. N for HEU at baseline, 6 weeks, 6, 12, 18 and 24 months is 3730, 2346, 2177, 1915, 1006 and 710, respectively. N for unexposed at baseline, 6 weeks, 6, 12, 18 and 24 months is 8598, 6206, 6431, 6202, 1733 and 1216, respectively.

References

    1. World Health Organization. Global Update on the Health Sector Response to HIV, 2014. 2014Geneva: World Health Organization.
    1. Datta P, Embree JE, Kreiss JK, et al. Mother-to-child transmission of human immunodeficiency virus type 1: report from the Nairobi Study. J Infect Dis. 1994;170:1134–1140..
    1. O’Brien DP, Sauvageot D, Zachariah R, et al. ; Medecins Sans Frontieres. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS. 2006;20:1955–1960..
    1. Marinda E, Humphrey JH, Iliff PJ, et al. ; ZVITAMBO Study Group. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J. 2007;26:519–526..
    1. Becquet R, Marston M, Dabis F, et al. ; UNAIDS Child Survival Group. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLoS One. 2012;7:e28510.
    1. Koyanagi A, Humphrey JH, Ntozini R, et al. ; ZVITAMBO Study Group. Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy. Pediatr Infect Dis J. 2011;30:45–51..
    1. Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. Lancet Infect Dis. 2016;16:e92–e107..
    1. Arpadi SM. Growth failure in children with HIV infection. J Acquir Immune Defic Syndr. 2000;25(suppl 1):S37–S42..
    1. Humphrey JH, Iliff PJ, Marinda ET, et al. ; ZVITAMBO Study Group. Effects of a single large dose of vitamin A, given during the postpartum period to HIV-positive women and their infants, on child HIV infection, HIV-free survival, and mortality. J Infect Dis. 2006;193:860–871..
    1. Iliff PJ, Piwoz EG, Tavengwa NV, et al. ; ZVITAMBO Study Group. Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival. AIDS. 2005;19:699–708..
    1. Malaba LC, Iliff PJ, Nathoo KJ, et al. ; ZVITAMBO Study Group. Effect of postpartum maternal or neonatal vitamin A supplementation on infant mortality among infants born to HIV-negative mothers in Zimbabwe. Am J Clin Nutr. 2005;81:454–460..
    1. Humphrey JH, Hargrove JW, Malaba LC, et al. ; ZVITAMBO Study Group. HIV incidence among post-partum women in Zimbabwe: risk factors and the effect of vitamin A supplementation. AIDS. 2006;20:1437–1446..
    1. Piwoz EG, Iliff PJ, Tavengwa N, et al. An education and counseling program for preventing breast-feeding-associated HIV transmission in Zimbabwe: design and impact on maternal knowledge and behavior. J Nutr. 2005;135:950–955..
    1. Gibson RS. Principles of Nutritional Assessment. 1990New York: Oxford University Press.
    1. Capurro H, Konichezky S, Fonseca D, et al. A simplified method for diagnosis of gestational age in the newborn infant. J Pediatr. 1978;93:120–122..
    1. Victora CG, de Onis M, Hallal PC, et al. Worldwide timing of growth faltering: revisiting implications for interventions. Pediatrics. 2010;125:e473–e480..
    1. Prendergast AJ, Humphrey JH. The stunting syndrome in developing countries. Paediatr Int Child Health. 2014;34:250–265..
    1. Dewey KG, Adu-Afarwuah S. Systematic review of the efficacy and effectiveness of complementary feeding interventions in developing countries. Matern Child Nutr. 2008;4(suppl 1):24–85..
    1. Jones AD, Rukobo S, Chasekwa B, et al. Acute illness is associated with suppression of the growth hormone axis in Zimbabwean infants. Am J Trop Med Hyg. 2015;92:463–470..
    1. Prendergast A, Rukobo S, Chasekwa B, et al. Stunting is characterized by chronic inflammation in Zimbabwean infants. PLoS One. 2014;9:e86928.
    1. Humphrey JH. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet. 2009;374:1032–1035..
    1. Ram M, Gupte N, Nayak U, et al. ; SWEN India and BJMC-JHU Clinical Trials Study Team. Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India. BMC Infect Dis. 2012;12:282.
    1. Lepage P, Msellati P, Hitimana DG, et al. Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda, 1988 to 1993. Pediatr Infect Dis J. 1996;15:479–485..
    1. Webb AL, Manji K, Fawzi WW, et al. Time-independent maternal and infant factors and time-dependent infant morbidities including HIV infection, contribute to infant growth faltering during the first 2 years of life. J Trop Pediatr. 2009;55:83–90..
    1. Bailey RC, Kamenga MC, Nsuami MJ, et al. Growth of children according to maternal and child HIV, immunological and disease characteristics: a prospective cohort study in Kinshasa, Democratic Republic of Congo. Int J Epidemiol. 1999;28:532–540..
    1. Bobat R, Coovadia H, Moodley D, et al. Growth in early childhood in a cohort of children born to HIV-1-infected women from Durban, South Africa. Ann Trop Paediatr. 2001;21:203–210..
    1. Berhane R, Bagenda D, Marum L, et al. Growth failure as a prognostic indicator of mortality in pediatric HIV infection. Pediatrics. 1997;100:E7.
    1. Patel D, Bland R, Coovadia H, et al. Breastfeeding, HIV status and weights in South African children: a comparison of HIV-exposed and unexposed children. AIDS. 2010;24:437–445..
    1. Henderson RA, Miotti PG, Saavedra JM, et al. Longitudinal growth during the first 2 years of life in children born to HIV-infected mothers in Malawi, Africa. Pediatr AIDS HIV Infect. 1996;7:91–97..
    1. McKinney RE, Robertson JW. Effect of human immunodeficiency virus infection on the growth of young children. Duke Pediatric AIDS Clinical Trials Unit. J Pediatr. 1993;123:579–582..
    1. Muhangi L, Lule SA, Mpairwe H, et al. Maternal HIV infection and other factors associated with growth outcomes of HIV-uninfected infants in Entebbe, Uganda. Public Health Nutr. 2013;16:1548–1557..
    1. Sofeu CL, Warszawski J, Ateba Ndongo F, et al. ; ANRS-PEDIACAM Study Group. Low birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon. PLoS One. 2014;9:e93554.
    1. Powis KM, Lei Q, Chinyanga Y, et al. Malnutrition Among HIV-exposed Uninfected Children in Botswana. Conference on Retroviruses and Opportunistic Infections. 2015Seattle, WA.
    1. Moraleda C, de Deus N, Serna-Bolea C, et al. Impact of HIV exposure on health outcomes in HIV-negative infants born to HIV-positive mothers in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2014;65:182–189..
    1. Slogrove A, Reikie B, Naidoo S, et al. HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life. J Trop Pediatr. 2012;58:505–508..
    1. Fox MP, Brooks DR, Kuhn L, et al. Role of breastfeeding cessation in mediating the relationship between maternal HIV disease stage and increased child mortality among HIV-exposed uninfected children. Int J Epidemiol. 2009;38:569–576..
    1. Kuhn L, Sinkala M, Semrau K, et al. Elevations in mortality associated with weaning persist into the second year of life among uninfected children born to HIV-infected mothers. Clin Infect Dis. 2010;50:437–444..
    1. Wei R, Msamanga GI, Spiegelman D, et al. Association between low birth weight and infant mortality in children born to human immunodeficiency virus 1-infected mothers in Tanzania. Pediatr Infect Dis J. 2004;23:530–535..
    1. Slyker JA, Patterson J, Ambler G, et al. Correlates and outcomes of preterm birth, low birth weight, and small for gestational age in HIV-exposed uninfected infants. BMC Pregnancy Childbirth. 2014;14:7.
    1. Kourtis AP, Wiener J, Kayira D, et al. Health outcomes of HIV-exposed uninfected African infants. AIDS. 2013;27:749–759..
    1. Sudfeld CR, Lei Q, Chinyanga Y, et al. Linear growth faltering among HIV-exposed uninfected children. J Acquir Immune Defic Syndr. 2016;73:182–189..
    1. Evans C, Humphrey JH, Ntozini R, et al. HIV-exposed uninfected infants in Zimbabwe: insights into health outcomes in the pre-antiretroviral therapy era. Front Immunol. 2016;7:190.
    1. McGrath CJ, Nduati R, Richardson BA, et al. The prevalence of stunting is high in HIV-1-exposed uninfected infants in Kenya. J Nutr. 2012;142:757–763..

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere